Alzheimer's and Parkinson's diseases are associated with the formation in the brain of amyloid fibrils from β-amyloid and α-synuclein proteins, respectively. It is likely that oligomeric fibrillization intermediates (protofibrils), rather than the fibrils themselves, are pathogenic, but the mechanism by which they cause neuronal death remains a mystery. We show here that mutant amyloid proteins associated with familial Alzheimer's and Parkinson's diseases form morphologically indistinguishable annular protofibrils that resemble a class of pore-forming bacterial toxins, suggesting that inappropriate membrane permeabilization might be the cause of cell dysfunction and even cell death in amyloid diseases.
The possibility that a molecular species other than the amyloid fibril could be pathogenic arose when oligomeric species rich in β-sheet structure (protofibrils) were found to be discrete intermediates in the fibrillization of β-amyloid (Aβ) and of α-synuclein in vitro1,2. An intermediate protofibril might therefore be pathogenic and be 'detoxified' by conversion to a fibril, as suggested by three general observations: there is no correlation between the quantity of fibrillar deposits at autopsy and the clinical severity of Alzheimer's or Parkinson's disease; transgenic mouse models of these conditions have disease-like phenotypes before fibrillar deposits can be detected1,2; and non-fibrillar Aβ oligomers are toxic in cell culture3,4 and have activity in vivo5.
Toxic protofibrils have been implicated in other neurodegenerative diseases as well as in systemic amyloidoses such as type II diabetes (in which the amyloid protein is IAPP)6 and familial amyloidotic polyneuropathy (in which it is transthyretin)7. Strikingly, protofibrils comprising proteins that are not associated with any disease are also toxic, suggesting that toxicity might arise from a shared structural feature of these intermediates8.
The pathogenic-protofibril hypothesis is supported by biophysical studies of variants of Aβ and α-synuclein linked to autosomal-dominant forms of Alzheimer's and Parkinson's diseases, respectively. The 'Arctic' mutation in amyloid-precursor protein, unlike all other mutations associated with Alzheimer's disease, reduces the total concentration of circulating Aβ, but mutant AβARC forms protofibrils in vitro more rapidly and to a greater extent than the wild-type form9.
The A30P and A53T α-synuclein mutations associated with Parkinson's disease (in which an alanine residue is replaced by phenylalanine at position 30 or by threonine at position 53, respectively) both promote protofibril formation in vitro relative to wild-type α-synuclein2. We examined the structural properties of A30P, A53T and AβARC protofibrils for shared structural features that might be related to their toxicity.
Heterogeneous populations of A30P, A53T and AβARC protofibrils were fractionated by gel-filtration chromatography (H.A.L. et al., unpublished results). The fraction with the smallest A30P and A53T protofibrils contained β-sheet-rich (as measured by circular dichroism) oligomers comprising 20–25 α-synuclein molecules (relative molecular mass, 320K–380K; 22–26 monomers; H.A.L. et al., unpublished results). Analysis of this fraction by electron microscopy revealed annular species (diameter 8–12 nm; inner diameter 2.0–2.5 nm) and coiled species, both of which seemed to be related to the spherical and chain-like species reported earlier2. Protofibrillar AβARC, fractionated by a similar method, contained many annular species of similar appearance (Fig. 1), diameter (7–10 nm; inner diameter 1.5–2.0 nm) and relative molecular mass (150K–250K, 40–60 AβARC molecules).
The pore-like morphology of a subpopulation of amyloid protofibrils might explain the pore activity of α-synuclein protofibrils in vesicle-permeabilization models10 and the channel-like properties of Aβ (ref. 11). Other amyloid proteins, including huntingtin (in Huntington's disease)12 and IAPP6,12, also have pore-like activity in vitro. The small annular Aβ and α-synuclein protofibrils (Fig. 1) resemble the cytolytic β-barrel pore-forming toxins from bacteria such as Clostridium perfringens13.
As expected, amyloid pores are formed much less efficiently than bacterial pores, which during the course of evolution have optimized their ability to puncture host membranes. However, amyloid pores might be wholly or partly responsible for the cytotoxicity associated with the formation of amyloid fibrils in Alzheimer's and Parkinson's diseases and in other age-associated degenerative amyloid diseases.
Lansbury, P. T. Proc. Natl Acad. Sci. USA 96, 3342–3344 (1999).
Goldberg, M. S. & Lansbury, P. T. Nature Cell Biol. 2, E115–E119 (2000).
Hartley, D. M. et al. J. Neurosci. 19, 8876–8884 (1999).
Lambert, M. P. et al. Proc. Natl Acad. Sci. USA 95, 6448–6453 (1998).
Walsh, D. M. et al. Nature 416, 535–539 (2002).
Janson, J. et al. Diabetes 48, 491–498 (1999).
Sousa, M. M. et al. Am. J. Pathol. 159, 1993–2000 (2001).
Bucciantini, M. et al. Nature 416, 507–511 (2002).
Nilsberth, C. et al. Nature Neurosci. 4, 887–893 (2001).
Volles, M. J. & Lansbury, P. T. Biochemistry 41, 4595–4602 (2002).
Lin, H., Bhatia, R. & Lal, R. FASEB J. 15, 2433–2444 (2001).
Kagan, B. L., Hirakura, Y., Azimov, R. & Azimova, R. Brain Res. Bull. 56, 281–284 (2001).
Hotze, E. M. et al. J. Biol. Chem. 277, 11597–11605 (2002).
The authors declare no competing financial interests.
About this article
Cite this article
Lashuel, H., Hartley, D., Petre, B. et al. Amyloid pores from pathogenic mutations. Nature 418, 291 (2002). https://doi.org/10.1038/418291a
Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease
npj Parkinson's Disease (2022)
Nature Reviews Neuroscience (2022)
Carrying Excess Baggage Can Slowdown Life: Protein Clearance Machineries That Go Awry During Aging and the Relevance of Maintaining Them
Molecular Neurobiology (2022)
Journal of Molecular Modeling (2022)
Nature Reviews Neuroscience (2021)